CTLA4 and neoplasm: The presence of tumour‐infiltrating lymphocytes (TILs) and the expression of immune checkpoint molecules such as PD‐1 and CTLA‐4, as well as those key secretory factors, are indicative of the immune landscape within TC tumours.16